Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.160
Neutral
RSI(14)
45.151
Neutral
STOCH(KDJ)(9,3,3)
10.024
Oversold
ATR(14)
0.596
Low Volatility
CCI(14)
-107.654
Sell
Williams %R
88.947
Oversold
TRIX(12,20)
0.099
Sell
StochRSI(14)
25.272
Buy
Integra Lifesciences Holdings Corp
IART12.660USD
+0.070+0.56%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
985.39MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Integra Lifesciences Holdings Corp
Currency: USD Updated: 2025-12-24Key Insights
Integra Lifesciences Holdings Corp's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 93/206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 15.50.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Integra Lifesciences Holdings Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
12
analysts
Hold
Current Rating
15.500
Target Price
+19.05%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Integra Lifesciences Holdings Corp Highlights
StrengthsRisks
Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is -1.96, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 73.55M shares, decreasing 25.42% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 634.00 shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-24The current financial score of Integra Lifesciences Holdings Corp is 6.43, ranking 153/206 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 402.06M, representing a year-over-year increase of 5.57%, while its net profit experienced a year-over-year increase of 49.47%.
Score
Financials
5.31
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
2.55
Operational Efficiency
8.70
Growth Potential
8.31
Shareholder Returns
7.30
Integra Lifesciences Holdings Corp's Company Valuation
Currency: USD Updated: 2025-12-24The current valuation score of Integra Lifesciences Holdings Corp is 8.05, ranking 48/206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -1.96, which is -5600.18% below the recent high of 107.70 and -15309.27% above the recent low of -301.73.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 93/206
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-24The current earnings forecast score of Integra Lifesciences Holdings Corp is 6.00, ranking 174/206 in the Healthcare Equipment & Supplies industry. The average price target for Integra Lifesciences Holdings Corp is 13.00, with a high of 25.00 and a low of 10.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
12
analysts
Hold
Current Rating
15.500
Target Price
+19.05%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
112
Total
6
Median
9
Average
Company name
Ratings
Analysts
Integra Lifesciences Holdings Corp
IART
12
Medtronic PLC
MDT
35
Stryker Corp
SYK
32
Abbott Laboratories
ABT
31
Dexcom Inc
DXCM
31
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
23
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-24The current price momentum score of Integra Lifesciences Holdings Corp is 5.96, ranking 162/206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 13.86 and the support level at 11.96, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
12.704
Sell
MA10
13.050
Sell
MA20
13.156
Sell
MA50
13.155
Sell
MA100
13.749
Sell
MA200
14.452
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-24The current institutional shareholding score of Integra Lifesciences Holdings Corp is 10.00, ranking 1/206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 94.42%, representing a quarter-over-quarter decrease of 17.69%. The largest institutional shareholder is The Vanguard, holding a total of 7.29M shares, representing 9.36% of shares outstanding, with 2.68% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
TRU ST Partnership, L.P.
Rubric Capital Management LP
Fuller & Thaler Asset Management Inc.
Dimensional Fund Advisors, L.P.
Invesco Advisers, Inc.
State Street Investment Management (US)
Boston Management and Research
Paradigm Capital Management, Inc.
1
2
Risk Assessment
Currency: USD Updated: 2025-12-24The current risk assessment score of Integra Lifesciences Holdings Corp is 4.66, ranking 99/206 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.03. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.03
VaR
+3.85%
240-Day Maximum Drawdown
+58.38%
240-Day Volatility
+62.21%
Return
Best Daily Return
60 days
+8.96%
120 days
+8.96%
5 years
+25.10%
Worst Daily Return
60 days
-23.46%
120 days
-23.46%
5 years
-23.46%
Sharpe Ratio
60 days
-0.08
120 days
+0.12
5 years
-0.56
Risk Assessment
Maximum Drawdown
240 days
+58.38%
3 years
+81.26%
5 years
+85.58%
Return-to-Drawdown Ratio
240 days
-0.72
3 years
-0.32
5 years
-0.19
Skewness
240 days
-1.16
3 years
-1.05
5 years
-1.00
Volatility
Realised Volatility
240 days
+62.21%
5 years
+44.70%
Standardised True Range
240 days
+6.64%
5 years
+10.46%
Downside Risk-Adjusted Return
120 days
+14.40%
240 days
+14.40%
Maximum Daily Upside Volatility
60 days
+38.10%
Maximum Daily Downside Volatility
60 days
+61.40%
Liquidity
Average Turnover Rate
60 days
+1.71%
120 days
+1.52%
5 years
--
Turnover Deviation
20 days
+41.37%
60 days
+35.25%
120 days
+20.09%
Peer Comparison
Healthcare Equipment & Supplies
Integra Lifesciences Holdings Corp
IART
6.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
EW
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
AORT
8.64 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Tactile Systems Technology Inc
TCMD
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AXGN
8.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
UFP Technologies Inc
UFPT
8.31 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Integra Lifesciences Holdings Corp?
The TradingKey Stock Score provides a comprehensive assessment of Integra Lifesciences Holdings Corp based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Integra Lifesciences Holdings Corp’s performance and outlook.
How do we generate the financial health score of Integra Lifesciences Holdings Corp?
To generate the financial health score of Integra Lifesciences Holdings Corp, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Integra Lifesciences Holdings Corp's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Integra Lifesciences Holdings Corp.
How do we generate the company valuation score of Integra Lifesciences Holdings Corp?
To generate the company valuation score of Integra Lifesciences Holdings Corp, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Integra Lifesciences Holdings Corp’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Integra Lifesciences Holdings Corp’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Integra Lifesciences Holdings Corp.
How do we generate the earnings forecast score of Integra Lifesciences Holdings Corp?
To calculate the earnings forecast score of Integra Lifesciences Holdings Corp, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Integra Lifesciences Holdings Corp’s future.
How do we generate the price momentum score of Integra Lifesciences Holdings Corp?
When generating the price momentum score for Integra Lifesciences Holdings Corp, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Integra Lifesciences Holdings Corp’s prices. A higher score indicates a more stable short-term price trend for Integra Lifesciences Holdings Corp.
How do we generate the institutional confidence score of Integra Lifesciences Holdings Corp?
To generate the institutional confidence score of Integra Lifesciences Holdings Corp, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Integra Lifesciences Holdings Corp’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Integra Lifesciences Holdings Corp.
How do we generate the risk management score of Integra Lifesciences Holdings Corp?
To assess the risk management score of Integra Lifesciences Holdings Corp, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Integra Lifesciences Holdings Corp’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Integra Lifesciences Holdings Corp.
